VRUS admitted (on today’s MS webcast) that the data showing SVR potential for Clevudine in HBV is largely anecdotal.
I’ve long thought that VRUS has been overstating the case that Clevudine is unique among HBV nucleoside/nucleotide drugs in its ability to generate an SVR (#msg-23359068).
Market Data 
Markets 
AI
